A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01).

Aaron Scott,Steven J. Cohen,Atrayee Basu-Mallick,Efrat Dotan,P J Gold,Howard S. Hochster,Somasundaram Subramaniam,Afsaneh Barzi,Patrick Jud Blatchford,Wells A. Messersmith

A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01).

2020

Aaron Scott
Steven J. Cohen
Atrayee Basu-Mallick
Efrat Dotan
P J Gold
Howard S. Hochster
Somasundaram Subramaniam
Afsaneh Barzi
Patrick Jud Blatchford
Wells A. Messersmith

103Background: Therapeutic resistance to antiangiogenics in metastatic colorectal cancer (mCRC) inevitably develops via multiple mechanisms including upregulation of the MET kinase pathway. Cabozan...

Keywords:

therapeutic resistance
Cabozantinib
Internal medicine
Phases of clinical research
Downregulation and upregulation
Oncology
Medicine
Colorectal cancer
Kinase
Pathology
Refractory
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations